

# References

## Chapter 16

- 1 Hansel TT, Barnes PJ. Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. *Drugs of Today*. 2002;**38**(9):585–600.
- 2 Walley T, Folino-Gallo P, Stephens P, Van Ganse E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997–2003. *British Journal of Clinical Pharmacology*. 2005;**60**(5):543–51.
- 3 French Health Authority. Report on Efficacy and Effectiveness of Lipid-Lowering Agents. Analyses Focused on Statins. French Health Authority, 2009.
- 4 Maggini M, Raschetti R, Traversa G, Bianchi C, Caffari B, Da Cas R, et al. The cerivastatin withdrawal crisis: a ‘post-mortem’ analysis. *Health Policy*. 2004;**69**(2):151–7.
- 5 Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. GINA Report. 2014. Available from: [http://www.ginasthma.org/local/uploads/files/GINA\\_Report\\_2015\\_Aug11.pdf](http://www.ginasthma.org/local/uploads/files/GINA_Report_2015_Aug11.pdf) (last accessed 18 November 2015).
- 6 Barnes PJ. Theophylline. *American Journal of Respiratory and Critical Care Medicine*. 2013;**188**(8):901–6.
- 7 Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet*. 1994;**344**(8934):1383–9.
- 8 European Medicines Agency. European Medicines Agency recommends withdrawal of dextropropoxyphene-containing medicines. 2009. Available from: [http://www.ema.europa.eu/ema/index.jsp?curl=pages/news\\_and\\_events/news/2009/11/news\\_detail\\_000074.sjsp](http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2009/11/news_detail_000074.sjsp) (last accessed 18 November 2015).
- 9 Hsiao FY, Tsai YW, Huang WF. Changes in physicians’ practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan. *Clinical Therapeutics*. 2009;**31**(11):2618–27.
- 10 Sun SX, Lee KY, Bertram CT, Goldstein JL. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. *Current Medical Research and Opinion*. 2007;**23**(8):1859–66.
- 11 Wurst KE, Poole C, Ephross SA, Olshan AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. *Birth Defects Research A Clinical and Molecular Teratology*. 2010;**88**(3):159–70.
- 12 Bobo WV, Epstein RA, Jr., Hayes RM, Shelton RC, Hartert TV, Mitchel E, et al. The effect of regulatory advisories on maternal antidepressant prescribing, 1995–2007: an interrupted time series study of 228 876 pregnancies. *Archives of Women’s Mental Health*. 2014;**17**(1):17–26.
- 13 Damiani G, Federico B, Anselmi A, Bianchi CB, Silvestrini G, Iodice L, et al. The impact of regional co-payment and national reimbursement criteria on statins use in Italy: an interrupted time-series analysis. *BMC Health Services Research*. 2014;**14**:6.
- 14 Hynd A, Roughead EE, Preen DB, Glover J, Bulsara M, Semmens J. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia. *Pharmacoepidemiology & Drug Safety*. 2008;**17**(11):1091–9.
- 15 Armour C, Bosnic-Anticevich S, Brilliant M, Burton D, Emmerton L, Krass I, et al. Pharmacy Asthma Care Program (PACP) improves outcomes for patients in the community. *Thorax*. 2007;**62**(6):496–502.
- 16 Bunting BA, Cranor CW. The Asheville Project: long-term clinical, humanistic, and economic out-

- comes of a community-based medication therapy management program for asthma. *Journal of the American Pharmacists Association*. 2006;**46**(2):133–47.
- 17 Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. *Lancet*. 2005;**365**(9459):579–87.
- 18 Sabuncu E, David J, Bernede-Bauduin C, Pepin S, Leroy M, Boelle PY, et al. Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002–2007. *PLoS Medicine*. 2009;**6**(6):e1000084.
- 19 Redshaw CH, Stahl-Timmins WM, Fleming LE, Davidson I, Depledge MH. Potential changes in disease patterns and pharmaceutical use in response to climate change. *Journal of Toxicology & Environmental Health B Critical Reviews*. 2013;**16**(5):285–320.
- 20 Yang BM, Prescott N, Bae EY. The impact of economic crisis on health-care consumption in Korea. *Health Policy Plan*. 2001;**16**(4):372–85.
- 21 Souliotis K, Papageorgiou M, Politi A, Ioakeimidis D, Sidiropoulos P. Barriers to accessing biologic treatment for rheumatoid arthritis in Greece: the unseen impact of the fiscal crisis – the Health Outcomes Patient Environment (HOPE) study. *Rheumatology International*. 2014;**34**(1):25–33.
- 22 Economou M, Madianos M, Peppou LE, Patelakis A, Stefanis CN. Major depression in the era of economic crisis: a replication of a cross-sectional study across Greece. *Journal of Affective Disorders*. 2013;**145**(3):308–14.
- 23 Berger P, Micallef J, Barrau K, Manuel C, Auquier P. [Anti-hepatitis B vaccination: after the health authorities' decision]. *Presse Médicale*. 1999;**28**(31):1702–6.
- 24 Denis F, Levy-Bruhl D. Mass vaccination against hepatitis B: the French example. *Current Topics in Microbiology & Immunology*. 2006;**304**:115–29.
- 25 Perquin M, Keipes M, Wirion R, Haas N, de Beaufort CE, Michel GH. [Development of the medical treatment of diabetes in Luxembourg]. *Bulletin de la Société des Sciences Médicales du Grand-Duché de Luxembourg*. 2006;**1**:29–35.
- 26 Kusnik-Joinville O, Weill A, Salanave B, Ricordeau P, Allemand H. Prevalence and treatment of diabetes in France: trends between 2000 and 2005. *Diabetes Metabolism*. 2008;**34**(3):266–72.
- 27 Socan M, Erculj V, Lajovic J. Early detection of influenza like illness through medication sales. *Central European Journal of Public Health*. 2012;**20**(2):156–62.
- 28 Aramini J, Muchaal PK, Pollari F. Value of pharmacy-based influenza surveillance – Ontario, Canada, 2009. *Morbidity and Mortality Weekly Report*. 2013;**62**(20):401–4.
- 29 Fuhrman C, Sarter H, Thibaudon M, Delmas MC, Zeghnoun A, Lecadet J, et al. Short-term effect of pollen exposure on antiallergic drug consumption. *Annals of Allergy, Asthma & Immunology*. 2007;**99**(3):225–31.
- 30 Van Ganse E., Harf R., Déchamp C., Clouet F, Daurès JP, Jacquier A., et al. *Relationship between Ragweed Pollination Counts and Delivery of Antiallergic Medication*. Stockohlm, European Respiratory Society, 2002.
- 31 Menichini F, Mudu P. Drug consumption and air pollution: an overview. *Pharmacoepidemiology and Drug Safety*. 2010;**19**(12):1300–15.
- 32 Chimonas MA, Gessner BD. Airborne particulate matter from primarily geologic, non-industrial sources at levels below National Ambient Air Quality Standards is associated with outpatient visits for asthma and quick-relief medication prescriptions among children less than 20 years old enrolled in Medicaid in Anchorage, Alaska. *Environmental Research*. 2007;**103**(3):397–404.
- 33 Vegni FE, Castelli B, Auxilia F, Wilkinson P. Air pollution and respiratory drug use in the city of Como, Italy. *European Journal of Epidemiology*. 2005;**20**(4):351–8.
- 34 Ilyas S, Moncrieff J. Trends in prescriptions and costs of drugs for mental disorders in England, 1998–2010. *British Journal of Psychiatry*. 2012;**200**(5):393–8.
- 35 European Centre for Disease Prevention and Control. *Surveillance of Invasive Bacterial Diseases in Europe, 2011*. Stockholm, European Centre for Disease Prevention and Control, 2013.
- 36 Adriaenssens N, Coenen S, Versporten A, Muller A, Vankerckhoven V, Goossens H. European Surveillance of Antimicrobial Consumption (ESAC): quality appraisal of antibiotic use in Europe. *Journal of Antimicrobial Chemotherapy*. 2011;**66**(Suppl. 6):vi71–7.
- 37 Adriaenssens N, Coenen S, Versporten A, Muller A, Minalu G, Faes C, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe (1997–2009). *Journal of Antimicrobial Chemotherapy*. 2011;**66**(Suppl. 6):vi3–12.

- 
- 38** Coenen S, Ferech M, Haaijer-Ruskamp FM, Butler CC, Vander Stichele RH, Verheij TJ, et al. European Surveillance of Antimicrobial Consumption (ESAC): quality indicators for outpatient antibiotic use in Europe. *Quality & Safety in Health Care*. 2007;**16**(6):440–5.
- 39** Goossens H, Guillemot D, Ferech M, Schlemmer B, Costers M, van Breda M, et al. National campaigns to improve antibiotic use. *European Journal of Clinical Pharmacology*. 2006;**62**(5):373–9.
- 40** Bauraind I, Lopez-Lozano JM, Beyaert A, Marchal JL, Seys B, Yane F, et al. Association between antibiotic sales and public campaigns for their appropriate use. *Journal of the American Medical Association*. 2004;**292**(20):2468–70.
- 41** Goossens H, Coenen S, Costers M, De Corte S, De Sutter A, Gordts B, et al. Achievements of the Belgian Antibiotic Policy Coordination Committee (BAP-COC). *Euro Surveillance*. 2008;**13**(46). pii: 19036.
- 42** Adriaenssens N, Coenen S, Muller A, Vankerckhoven V, Goossens H. European Surveillance of Antimicrobial Consumption (ESAC): outpatient systemic antimycotic and antifungal use in Europe. *Journal of Antimicrobial Chemotherapy*. 2010;**65**(4):769–74.